BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vosoughi R, Marriott JJ. Thrombotic microangiopathy in Interferon Beta treated multiple sclerosis patients: Review of literature and report of two new cases. Mult Scler Relat Disord. 2014;3:321-325. [PMID: 25876469 DOI: 10.1016/j.msard.2013.12.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Kundra A, Wang JC. Interferon induced thrombotic microangiopathy (TMA): Analysis and concise review. Crit Rev Oncol Hematol. 2017;112:103-112. [PMID: 28325251 DOI: 10.1016/j.critrevonc.2017.02.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.6] [Reference Citation Analysis]
2 Dumitrescu L, Constantinescu CS, Tanasescu R. Recent developments in interferon-based therapies for multiple sclerosis. Expert Opin Biol Ther 2018;18:665-80. [PMID: 29624084 DOI: 10.1080/14712598.2018.1462793] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
3 Iacopo G, Allinovi M, Caroti L, Cirami LC. Broad spectrum of interferon-related nephropathies—glomerulonephritis, systemic lupus erythematosus-like syndrome and thrombotic microangiopathy: A case report and review of literature. WJN 2019;8:109-17. [DOI: 10.5527/wjgo.v8.i7.109] [Reference Citation Analysis]
4 Dauvergne M, Buob D, Rafat C, Hennino MF, Lemoine M, Audard V, Chauveau D, Ribes D, Cornec-Le Gall E, Daugas E, Pillebout E, Vuiblet V, Boffa JJ; French Nephropathology Group. Renal diseases secondary to interferon-β treatment: a multicentre clinico-pathological study and systematic literature review. Clin Kidney J 2021;14:2563-72. [PMID: 34950468 DOI: 10.1093/ckj/sfab114] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Auricchio F, Scavone C, Cimmaruta D, Di Mauro G, Capuano A, Sportiello L, Rafaniello C. Drugs approved for the treatment of multiple sclerosis: review of their safety profile. Expert Opin Drug Saf 2017;16:1359-71. [PMID: 28976217 DOI: 10.1080/14740338.2017.1388371] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 5.6] [Reference Citation Analysis]
6 Nishio H, Tsukamoto T, Matsubara T, Okada Y, Takahashi R, Yanagita M. Thrombotic microangiopathy caused by interferon β-1b for multiple sclerosis: a case report. CEN Case Rep 2016;5:179-83. [PMID: 28508977 DOI: 10.1007/s13730-016-0220-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
7 Allinovi M, Cirami CL, Caroti L, Antognoli G, Farsetti S, Amato MP, Minetti EE. Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab. Clin Kidney J. 2017;10:625-631. [PMID: 28980667 DOI: 10.1093/ckj/sfw143] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
8 Gianassi I, Allinovi M, Caroti L, Cirami LC. Broad spectrum of interferon-related nephropathies-glomerulonephritis, systemic lupus erythematosus-like syndrome and thrombotic microangiopathy: A case report and review of literature. World J Nephrol 2019; 8(7): 109-117 [PMID: 31750091 DOI: 10.5527/wjn.v8.i7.109] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Klotz L, Berthele A, Brück W, Chan A, Flachenecker P, Gold R, Haghikia A, Hellwig K, Hemmer B, Hohlfeld R, Korn T, Kümpfel T, Lang M, Limmroth V, Linker RA, Meier U, Meuth SG, Paul F, Salmen A, Stangel M, Tackenberg B, Tumani H, Warnke C, Weber MS, Ziemssen T, Zipp F, Wiendl H. [Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action]. Nervenarzt 2016;87:645-59. [PMID: 26927677 DOI: 10.1007/s00115-016-0077-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
10 Ben-Amor AF, Trochanov A, Fischer TZ. Cumulative Review of Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura, and Hemolytic Uremic Syndrome Reports with Subcutaneous Interferon β-1a. Adv Ther 2015;32:445-54. [PMID: 25991578 DOI: 10.1007/s12325-015-0212-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
11 Kavanagh D, McGlasson S, Jury A, Williams J, Scolding N, Bellamy C, Gunther C, Ritchie D, Gale DP, Kanwar YS, Challis R, Buist H, Overell J, Weller B, Flossmann O, Blunden M, Meyer EP, Krucker T, Evans SJ, Campbell IL, Jackson AP, Chandran S, Hunt DP. Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature. Blood. 2016;128:2824-2833. [PMID: 27663672 DOI: 10.1182/blood-2016-05-715987] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 9.2] [Reference Citation Analysis]
12 Mastorodemos VC, Ioannidis SG, Papadaki EZ, Mitsias PD. Posterior Reversible Encephalopathy Syndrome, Multiple Sclerosis and interferon therapy: Association, co-incidence or convoluted interplay? Mult Scler Relat Disord 2020;45:102356. [PMID: 32659736 DOI: 10.1016/j.msard.2020.102356] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Gerischer LM, Siebert E, Janke O, Jungehuelsing GJ, Ruprecht K. Favorable outcome of interferon-beta associated thrombotic microangiopathy following treatment with corticosteroids, plasma exchange and rituximab: A case report. Multiple Sclerosis and Related Disorders 2016;10:63-5. [DOI: 10.1016/j.msard.2016.09.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
14 Parisi M, Manni A, Caputo F, Trojano M, Paolicelli D. A case report of late-onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review. Brain Behav 2021;11:e01930. [PMID: 33325640 DOI: 10.1002/brb3.1930] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Omoto S, Utsumi T, Matsuno H, Terasawa Y, Iguchi Y. Thrombotic Microangiopathy Presenting with Intestinal Involvement Following Long-term Interferon-β1b Treatment for Multiple Sclerosis. Intern Med 2018;57:741-4. [PMID: 29151517 DOI: 10.2169/internalmedicine.9326-17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]